- Home
- KNSA vs BCAT Comparison
KNSA vs BCAT Comparison
Compare KNSA & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- BCAT
- Stock Information
- Founded
- KNSA 2015
- BCAT 2020
- Country
- KNSA United Kingdom
- BCAT United States
- Employees
- KNSA N/A
- BCAT N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- BCAT Finance/Investors Services
- Sector
- KNSA Health Care
- BCAT Finance
- Exchange
- KNSA Nasdaq
- BCAT Nasdaq
- Market Cap
- KNSA 1.4B
- BCAT 1.7B
- IPO Year
- KNSA 2018
- BCAT N/A
- Fundamental
- Price
- KNSA $20.02
- BCAT $15.36
- Analyst Decision
- KNSA Strong Buy
- BCAT
- Analyst Count
- KNSA 5
- BCAT 0
- Target Price
- KNSA $36.60
- BCAT N/A
- AVG Volume (30 Days)
- KNSA 567.6K
- BCAT 308.8K
- Earning Date
- KNSA 02-25-2025
- BCAT 01-01-0001
- Dividend Yield
- KNSA N/A
- BCAT 9.38%
- EPS Growth
- KNSA N/A
- BCAT N/A
- EPS
- KNSA N/A
- BCAT 1.43
- Revenue
- KNSA $384,098,000.00
- BCAT N/A
- Revenue This Year
- KNSA $60.10
- BCAT N/A
- Revenue Next Year
- KNSA $34.22
- BCAT N/A
- P/E Ratio
- KNSA N/A
- BCAT $11.41
- Revenue Growth
- KNSA 54.41
- BCAT N/A
- 52 Week Low
- KNSA $16.56
- BCAT $13.67
- 52 Week High
- KNSA $28.15
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- KNSA 53.15
- BCAT 39.90
- Support Level
- KNSA $19.31
- BCAT $15.62
- Resistance Level
- KNSA $20.20
- BCAT $15.91
- Average True Range (ATR)
- KNSA 0.80
- BCAT 0.14
- MACD
- KNSA 0.06
- BCAT -0.02
- Stochastic Oscillator
- KNSA 72.80
- BCAT 16.67
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.